News
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting
Providing live demonstrations of a PDT procedure using the RhodoLED® lamp at booth #2224WOBURN, MA / ACCESSWIRE / March 17, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today...
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
This press release corrects and replaces the press release published on 3/8/2023 at 4:03:00 PM ET, as the Adjusted EBITDA Reconciliation table was not included in all previously posted versions of the press release.WOBURN, MA / ACCESSWIRE / March 9, 2023 /...
Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
WOBURN, MA / ACCESSWIRE / March 8, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and twelve months ended December 31,...
Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023
WOBURN, MA / ACCESSWIRE / March 2, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products will be presenting at the 35th Annual ROTH Conference in Laguna Nigel, CA being held March 12-14,...
Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
WOBURN, MA / ACCESSWIRE / February 22, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December...
Biofrontera, Inc. to Present at Third Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 21st – 24th, 2023
WOBURN, MA / ACCESSWIRE / February 15, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor...
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the first patient has been dosed in a Phase 3 randomized, double-blind,...
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31,...
Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in the...
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly...